Trevmar

Trevor G Marshall, PhD Director, Autoimmunity Research Foundation http://TrevorMarshall.com

Trevor graduated in Electrical Engineering from the University of Adelaide, South Australia, in 1973. He spent a year as Tutor at the University of Technology in Lae, Papua New Guinea, and in 1975 took a post lecturing at W.A.I.T., Curtin University, in Western Australia. By 1978 he had transitioned to microcomputers, and he gained his Masters degree, by thesis, in 1978. Moving to the University of Western Australia he began work on his PhD thesis in Biomedicine, with clinical research at the Sir Charles Gairdner Hospital. Success using pulsatile LHRH to treat Cryptorchidism, and both Male and Female infertility, led to many publications and conference presentations during that early phase of his Biomedical career. In 1982 he moved to California, simultaneously beginning a collaboration with the Hospital for Sick Children, in Toronto, which led to his PhD thesis in 1984 - "Modelling and simulation in diabetes care." Through the decade of the 90's Trevor achieved acclaim as a pioneer in the design of high-powered multiprocessing computers, some of which were used in the early PET scanners. He was also at the forefront of the evolution of Internet and Linux technologies. At the turn of the millennium he returned to his Biomedical roots, intrigued by an observation that patients with Th1 immune disease sometimes reacted to administration of Angiotensin Receptor Blockers with neurologic manifestations, including psychedelic dreams.

His subsequent discoveries have shown that the inflammatory diseases often thought to be 'autoimmune'are caused by a defect in the innate immune system, and have very little to do with 'antibodies to self'. He and his colleagues have now completed 4 years of an innovative Phase 2 clinical study, and have shown that diagnoses ranging from Hashimoto's Thyroiditis, through Arthritis and Diabetes, to Multiple Sclerosis and Sarcoidosis all have the same basic pathogenesis - antibiotic-resistant bacteria which have evolved to live inside the cytoplasm of phagocytic cells."

The FDA has recently granted designations for the use of the antibacterial therapy he trialled in Sarcoidosis, and other FDA applications are in process for several other chronic indications.

His recent publications are catalogued at http://TrevorMarshall.com/papers.htm